Isosorbide di-(methyl fumarate)
Based on 1 Customer Validation
Isosorbide di-(methyl fumarate) (IDMF), topical DMF (HY-17363) derivative, is an NRF2/ARE pathway activator. Isosorbide di-(methyl fumarate) downregulates ANCR targets, modulates epithelial differentiation, represses proinflammatory cytokine genes, IL-17A- and TNF-induced keratinocyte genes, psoriatic skin lesion-specific genes, and immune response genes. Isosorbide di-(methyl fumarate) stimulates oxidative stress response gene transcription, reduces erythema and scaling in Imiquimod (HY-B0180)-induced psoriasiform lesions. Isosorbide di-(methyl fumarate) exhibits no genotoxicity or radiation sensitivity in skin fibroblasts, is nonirritating and nonsensitizing in rodent models. Isosorbide di-(methyl fumarate) can be used for the research of psoriasis vulgaris.
For research use only. We do not sell to patients.
- Purity : 99.87%
- CAS No.: 2013542-44-2
- Formula: C16H18O10
- Molecular Weight:370.31
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
In Vitro
Isosorbide di-(methyl fumarate) (25-100 μg/mL; 1 h) does not exhibit phototoxicity in neonatal human dermal fibroblasts[1].
Isosorbide di-(methyl fumarate) (1-200 μg/mL) does not exhibit mutagenic effects in Salmonella typhimurium strains TA1535 and TA1537[1].
Isosorbide di-(methyl fumarate) (24 h) upregulates genes associated with oxidative stress response and xenobiotic metabolism, while downregulating genes associated with immune response and epithelial differentiation, in cytokine-stimulated human keratinocytes[1].
Isosorbide di-(methyl fumarate) (1-10 μg/mL; 24 h) activates the NRF2/ARE pathway in human embryonic kidney 293 cells, with significant increases in the expression of the luciferase re-
porter gene[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Neonatal human dermal fibroblasts
-
Concentration:25, 50, 100 μg/mL
-
Incubation Time:1 h
-
Result:Resulted in neutral red uptake of 97.1% in UVA(-) cells and 84.7% in UVA(+) cells at 25 μg/mL.
Resulted in neutral red uptake of 57.5% in UVA(-) cells and 53% in UVA(+) cells at 50 μg/mL.
Resulted in neutral red uptake of 1.3% in UVA(-) cells and 0.3% in UVA(+) cells at 100 μg/mL.
Showed UVA treatment significantly reduced viability at 0, 25, and 50 μg/mL, but the magnitude of reduction was similar between UVA(-) and UVA(+) cells at each concentration, indicating no phototoxic effect.
In Vivo
Isosorbide di-(methyl fumarate) (200-2000 mg/kg; topical; single dose) in female Wistar rats cause no acute dermal toxicity, skin irritation, or systemic adverse effects[1].
Isosorbide di-(methyl fumarate) (500 mg; topical; single dose; 4 h) in male New Zealand White rabbits causes only transient, very slight skin irritation that resolves rapidly[1].
Isosorbide di-(methyl fumarate) (100 mg; topical; 6 hours on days 0, 7, 14 (induction); 6 hours on day 28 (challenge)) in Hartley guinea pigs does not elicit skin sensitization or systemic adverse effects[1].
Isosorbide di-(methyl fumarate) (5% lotion; topical; once daily; 6 days) significantly reduces erythema, scaling, and skin thickness in Imiquimod (HY-B0180)-induced psoriasiform mouse lesions, while modulating gene expression to repress immune responses and support epidermal development[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male, 5-7 weeks old)[1]
-
Dosage:100 mg of IDMF topical cream
-
Administration:topical; once daily (5 days/week); 13 days
-
Result:Did not cause erythema or increase skin scale.
Increased the granular layer by 28% and orthokeratosis by 34.5%.
No leukocytic infiltrate, parakeratosis, or hyperkeratosis was observed.
-
Animal Model:BALB/c (male, 8-9 weeks old, psoriasiform lesions induced by daily topical 5% Imiquimod cream for 5 days)[1]
-
Dosage:5% IDMF lotion
-
Administration:topical; once daily; 6 days (1 hour after imiquimod on days 1-5, alone on day 6)
-
Result:Significantly reduced skin erythema on days 5 and 6.
Reduced skin scaling/flaking and skin thickness on day 6.
Upregulated 68 genes associated with hair cycle and epidermis development.
Downregulated 98 genes associated with immune response activation, granulocyte migration, and immune effector process.
Chemical Information
-
CAS No. 2013542-44-2
-
Appearance Solid
-
Molecular Weight 370.31
-
Formula C16H18O10
-
Color White to light yellow
-
SMILES
COC(/C=C/C(O[C@H]1[C@]2([H])[C@@](OC1)([H])[C@H](CO2)OC(/C=C/C(OC)=O)=O)=O)=O
-
Synonyms
IDMF
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 33.33 mg/mL (90.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Imiquimod-Induced Psoriasiform Dermatitis
Imiquimod (IMQ)-induced psoriasiform dermatitis is a widely used murine model in which topical application of IMQ, a Toll-like receptor 7 (TLR7) agonist, triggers innate immune activation in the skin and induces a psoriasis-like inflammatory cascade characterized by epidermal hyperplasia, immune cell infiltration, and cytokine production dominated by the IL-23/IL-17 axis. This inflammatory response is mediated through activation of dendritic cells and downstream induction of IL-23, IL-17A, IL-22, and related pro-inflammatory mediators, recapitulating key features of human plaque psoriasis and enabling mechanistic and therapeutic studies. The model is commonly induced using Aldara (5% IMQ cream) applied topically to murine skin, resulting in rapid onset of erythema, scaling, and thickening that can be quantified as disease severity indices and validated histologically.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7004 mL | 13.5022 mL | 27.0044 mL | 67.5110 mL |
| 5 mM | 0.5401 mL | 2.7004 mL | 5.4009 mL | 13.5022 mL | |
| 10 mM | 0.2700 mL | 1.3502 mL | 2.7004 mL | 6.7511 mL | |
| 15 mM | 0.1800 mL | 0.9001 mL | 1.8003 mL | 4.5007 mL | |
| 20 mM | 0.1350 mL | 0.6751 mL | 1.3502 mL | 3.3756 mL | |
| 25 mM | 0.1080 mL | 0.5401 mL | 1.0802 mL | 2.7004 mL | |
| 30 mM | 0.0900 mL | 0.4501 mL | 0.9001 mL | 2.2504 mL | |
| 40 mM | 0.0675 mL | 0.3376 mL | 0.6751 mL | 1.6878 mL | |
| 50 mM | 0.0540 mL | 0.2700 mL | 0.5401 mL | 1.3502 mL | |
| 60 mM | 0.0450 mL | 0.2250 mL | 0.4501 mL | 1.1252 mL | |
| 80 mM | 0.0338 mL | 0.1688 mL | 0.3376 mL | 0.8439 mL |